Company

Explore the latest news from Etap-LAB

Contact an expert

Published on the 10 October 2023

ETAP-Lab announces the acquisition of SYNCROSOME

ETAP-Lab announces the acquisition of SYNCROSOME, a CRO specialising in preclinical in vivo pharmacology services focused on cardiovascular pathologies. 🚀 This represents a significant step forward in…

Company
Published on the 10 October 2023

SYNCROSOME is proud to announce that it has joined the ETAP-Lab group

SYNCROSOME is proud to announce that it has joined the ETAP-Lab group, an offshoot of the preclinical CRO ETAP-Lab. 🚀 This acquisition marks a new stage in the company's development. Since its i…

Company
Published on the 23 November 2021

New -French Tech Central opens an office in Caen, Normandy

24 Nov – Inauguration of the French Tech Central office in Caen – Annelise Letourneur (Assistant Director at STROK@LLIANCE ) will take part in a round table discussion at…

Company
Published on the 16 November 2021

Save the date – we’d love to meet you!

Discover ETAP-Lab and other biotech businesses at an Afterwork evening on November 18th, organised by Biovalley France. Nicolas Violle will be delighted to meet you and tell you about what we do at E…

Company
Published on the 5 November 2021

Renewal of ETAP-Lab’s ISO 9001 certification (v2015)!

Renewal of ETAP-Lab’s ISO 9001 certification (v2015)! A well-managed quality system is key to a high performance, trustworthy preclinical service. ETAP-Lab has been investing in quality management con…

Company
Published on the 1 October 2021

Now we are 4!

STROK@LLIANCE is celebrating it’s 4th anniversary!! With 35 preclinical studies under our belt, we’re proud to say we’ve already contributed to the progress of numerous R&D projects. Our tea…

Company
Published on the 19 July 2021

New Alzheimer’s model in the aged mouse: come and meet us at AAIC 2021

ETAP-Lab will present its new Alzheimer's model in the aged mouse at the Alzheimer's Association International Conference, to be held in Denver (USA) from 26 to 30 July 2021. Our expert, Dr. Ahmad All…

Company Science and innovation
Published on the 16 July 2021

ETAP-Lab’s human amyloid beta 1-42 oligomers (AβO) are disrupting functional neuronal network activity

Low non-cytotoxic doses of ETAP-Lab’s human amyloid beta 1-42 oligomers (AβO) are disrupting functional neuronal network activity in NETRI’s microfluidic device coupled with MEA. This result is an imp…

Company

Explore our scientific resources and browse posters…

Explore Our Resources